Nuclera: Valuation, Funding & Investors
Nuclera is a biotechnology company that accelerates drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System. The company combines cell-free expression systems, digital microfluidics, and multiplex protein screening to enable in-house protein expression, purification, and binding validation for biologics research.
Leadership & Board
- Current Number of Employees
- 108
- Current LinkedIn Followers
- 26,445
Latest Estimated Valuation
- Total Amount Raised
- $12M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $12M
- Latest Funding Round
- Series C
Company Momentum Positive
Nuclera LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Nuclera had 108 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Nuclera had 26,445 followers as of October 26, 2026. The number of followers increased by 56 (0.21%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 13, 2026 | Series C | $12.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| British Business Bank | Series C |
| Elevage Medical Technologies | Series C |
| Jonathan Milner | Series C |
| GK Goh | Series C |
Similar Companies
A snapshot of private companies similar to Nuclera, helping you discover and navigate related company profiles.
